Braveheart Bio insiders report 9.13M convertible shares

Braveheart Bio, Inc. received an initial beneficial ownership report from AH Bio Fund IV, L.P. and related entities regarding holdings in Series A Preferred Stock.

Rhea-AI Filing Summary

Braveheart Bio, Inc. received an initial beneficial ownership report from AH Bio Fund IV, L.P. and related entities regarding holdings in Series A Preferred Stock. This preferred stock is convertible into 9,132,420 shares of Common Stock on a 4.38-for-1 basis, at the option of the holder, and will convert automatically into that number of common shares immediately prior to the closing of the company’s initial public offering. The shares are held indirectly through AH Bio Fund IV, L.P. for itself and as nominee for several affiliated funds, with AH Equity Partners Bio IV, L.L.C. having sole voting and dispositive power. Marc Andreessen and Ben Horowitz, as managing members of AH Equity Partners Bio IV, may be deemed to share voting and dispositive power, while each reporting person disclaims group status and beneficial ownership except to the extent of any pecuniary interest.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider AH Bio Fund IV, L.P., AH Equity Partners Bio IV, L.L.C., Andreessen Marc L, HOROWITZ BENJAMIN A

Role 10% Owner | 10% Owner | 10% Owner | 10% Owner

Type	Security	Shares	Price	Value
holding	Series A Preferred Stock F1, F2, F3	--	--	--

Holdings After Transaction: Series A Preferred Stock — 9,132,420 contracts (Indirect, By AH Bio Fund IV, L.P.)

Footnotes (3)

1. F1. Series A Preferred Stock is convertible into Common Stock on a 4.38-for-1 basis at the option of the holder, and will convert automatically immediately prior to the closing of the Issuer's initial public offering into the number of shares of Common Stock shown in column 3 without payment of consideration. The Series A Preferred Stock has no expiration date.
2. F2. The reported securities are held by AH Bio Fund IV, L.P. ("AH Bio Fund IV"), for itself and as nominee for AH Bio Fund IV-B, L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual Fund-B, L.P., AH 2022 Annual Fund-QC, L.P. and CLF Partners III, LP. AH Equity Partners Bio IV, L.L.C. ("AH EP Bio IV") is the general partner of AH Bio Fund IV and has sole voting and dispositive power with regard to the securities held by AH Bio Fund IV for itself and as nominee. The managing members of AH EP Bio IV are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund IV for itself and as nominee.
3. F3. (Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund IV for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.

Key Figures

Underlying common shares: 9,132,420 shares Conversion ratio: 4.38-for-1 Expiration date: No expiration date +2 more

5 metrics

Underlying common shares 9,132,420 shares Common Stock underlying Series A Preferred Stock held indirectly by AH Bio Fund IV, L.P.

Conversion ratio 4.38-for-1 Series A Preferred Stock convertible into Common Stock on a 4.38-for-1 basis

Expiration date No expiration date Series A Preferred Stock has no expiration date

Number of reporting persons 4 AH Bio Fund IV, L.P.; AH Equity Partners Bio IV, L.L.C.; Marc Andreessen; Ben Horowitz

Ownership type Indirect Reported holdings are indirect, held by AH Bio Fund IV, L.P.

Key Terms

Series A Preferred Stock, 4.38-for-1 basis, initial public offering, dispositive power, +1 more

5 terms

Series A Preferred Stock financial

"Series A Preferred Stock is convertible into Common Stock on a 4.38-for-1 basis"

Series A preferred stock is a type of ownership share in a company that gives investors certain advantages, such as priority in receiving profits or getting their money back if the company is sold or goes bankrupt. It is often issued during early funding stages to attract investors by offering more security than common shares. This stock matters to investors because it provides a safer way to invest while still holding potential for future gains.

4.38-for-1 basis financial

"convertible into Common Stock on a 4.38-for-1 basis at the option of the holder"

initial public offering financial

"will convert automatically immediately prior to the closing of the Issuer's initial public offering"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

dispositive power financial

"has sole voting and dispositive power with regard to the securities held"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

pecuniary interest financial

"beneficial owner of such securities, except to the extent of such person's pecuniary interest"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership in Braveheart Bio, Inc. (BRVE) does AH Bio Fund IV report on this Form 3?

AH Bio Fund IV reports Series A Preferred Stock convertible into 9,132,420 shares of Braveheart Bio common stock. These shares are held indirectly for AH Bio Fund IV, L.P. and certain affiliated funds, as detailed in the filing footnotes.

How does the Series A Preferred Stock of BRVE convert into common stock?

The Series A Preferred Stock converts into BRVE common stock on a 4.38-for-1 basis at the option of the holder. It will also convert automatically into 9,132,420 common shares immediately before the closing of Braveheart Bio’s initial public offering.

Who has voting and dispositive power over the reported BRVE securities?

The filing states that AH Equity Partners Bio IV, L.L.C. is the general partner of AH Bio Fund IV and has sole voting and dispositive power over the securities held by AH Bio Fund IV for itself and as nominee for affiliated funds.

What roles do Marc Andreessen and Ben Horowitz have in the BRVE Form 3 filing?

Marc Andreessen and Ben Horowitz are identified as managing members of AH Equity Partners Bio IV, L.L.C. They may be deemed to share voting and dispositive power over the securities held by AH Bio Fund IV, subject to the beneficial ownership disclaimers.

Do the reporting persons claim beneficial ownership of the BRVE shares?

Each reporting person disclaims beneficial ownership of the securities held by AH Bio Fund IV, except to the extent of their pecuniary interest, and also disclaims the existence of a “group” for ownership purposes.

Does the Series A Preferred Stock of BRVE have an expiration date?

No. The filing specifies that the Series A Preferred Stock has no expiration date, remaining outstanding until converted into Braveheart Bio common stock under the stated terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 01:46 PM Accepted by SEC EDGAR 08/05/2026 - 09:17 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

AH Bio Fund IV, L.P.

(Last) (First) (Middle)

C/O ANDREESSEN HOROWITZ

2865 SAND HILL ROAD, SUITE 101

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/05/2026

3. Issuer Name and Ticker or Trading Symbol
Braveheart Bio, Inc. [ BRVE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Preferred Stock	(1)	(1)	Common Stock	9,132,420	(1)	I	By AH Bio Fund IV, L.P.(2)(3)

1. Name and Address of Reporting Person^*

AH Bio Fund IV, L.P.

(Last) (First) (Middle)

C/O ANDREESSEN HOROWITZ

2865 SAND HILL ROAD, SUITE 101

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

AH Equity Partners Bio IV, L.L.C.

(Last) (First) (Middle)

C/O ANDREESSEN HOROWITZ

2865 SAND HILL ROAD, SUITE 101

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Andreessen Marc L

(Last) (First) (Middle)

C/O ANDREESSEN HOROWITZ

2865 SAND HILL ROAD, SUITE 101

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

HOROWITZ BENJAMIN A

(Last) (First) (Middle)

C/O ANDREESSEN HOROWITZ

2865 SAND HILL ROAD, SUITE 101

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Series A Preferred Stock is convertible into Common Stock on a 4.38-for-1 basis at the option of the holder, and will convert automatically immediately prior to the closing of the Issuer's initial public offering into the number of shares of Common Stock shown in column 3 without payment of consideration. The Series A Preferred Stock has no expiration date.

2. The reported securities are held by AH Bio Fund IV, L.P. ("AH Bio Fund IV"), for itself and as nominee for AH Bio Fund IV-B, L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual Fund-B, L.P., AH 2022 Annual Fund-QC, L.P. and CLF Partners III, LP. AH Equity Partners Bio IV, L.L.C. ("AH EP Bio IV") is the general partner of AH Bio Fund IV and has sole voting and dispositive power with regard to the securities held by AH Bio Fund IV for itself and as nominee. The managing members of AH EP Bio IV are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund IV for itself and as nominee.

3. (Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund IV for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.

	AH Bio Fund IV, L.P., By AH Equity Partners Bio IV, L.L.C., Its General Partner, By /s/ Phil Hathaway, Chief Operating Officer	08/05/2026
	AH Equity Partners Bio IV, L.L.C., By /s/ Phil Hathaway, Chief Operating Officer	08/05/2026
	/s/ Phil Hathaway, Attorney-in-Fact for Marc L. Andreessen	08/05/2026
	/s/ Phil Hathaway, Attorney-in-Fact for Benjamin Horowitz	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)